Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 June 2021Website:
http://www.januxrx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 20 Jun 2024 22:36:39 GMTDividend
Analysts recommendations
Institutional Ownership
JANX Latest News
Investors seeking an adrenaline rush can easily experience it by investing in biotech stocks. There is an exciting element in investing in a company that is making critical decisions with life-saving drugs.
Janux (JANX) stock rises after reports suggest the company is considering a potential sale due to interest from major pharmaceutical companies.
Janux Therapeutics (JANX) is a promising choice for investors seeking stocks that are likely to continue their recent upward momentum, as it is among the stocks that have met our criteria for "Recent Price Strength."
Janux Therapeutics saw an increase in its stock price this week following reports that the company is considering a potential sale. The company has not confirmed or denied any ongoing acquisition talks.
Analysts' price targets for Janux Therapeutics (JANX) suggest a 40.3% potential increase in the stock. Although this widely-used measure may not always be accurate, the consensus among analysts in raising earnings estimates does indicate a positive outlook for the stock.
According to a media report, the biotech company is exploring the possibility of selling itself and has received buyout offers from pharmaceutical companies.
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
- 1(current)
What type of business is Janux Therapeutics?
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
What sector is Janux Therapeutics in?
Janux Therapeutics is in the Healthcare sector
What industry is Janux Therapeutics in?
Janux Therapeutics is in the Biotechnology industry
What country is Janux Therapeutics from?
Janux Therapeutics is headquartered in United States
When did Janux Therapeutics go public?
Janux Therapeutics initial public offering (IPO) was on 11 June 2021
What is Janux Therapeutics website?
https://www.januxrx.com
Is Janux Therapeutics in the S&P 500?
No, Janux Therapeutics is not included in the S&P 500 index
Is Janux Therapeutics in the NASDAQ 100?
No, Janux Therapeutics is not included in the NASDAQ 100 index
Is Janux Therapeutics in the Dow Jones?
No, Janux Therapeutics is not included in the Dow Jones index
When does Janux Therapeutics report earnings?
The next expected earnings date for Janux Therapeutics is 08 August 2024